The researchers are examining the effectiveness of COVID-19 vaccines against the SARS-CoV-2 Delta variant. The latest findings are discussed.
At the time of publication, all data and statistics are based on public data available. There may be outdated information. See our coronavirus exclusive section for the latest information about the COVID-19 pandemic and follow our live update page.
The first-identified SARS-CoV-2 delta variant in India now represents the dominant viral shape in the UK. In the USA, this variant accounts for at least 10% of new cases.
UK data shows that in the recent seven days new infections with SARS-CoV-2 increased by 31%. In addition, the Public Health England (PHE) analysis suggests that the delta variant is more transmissible than previous versions and is more likely to lead to hospital treatment.
Nevertheless, recent data show that vaccines can help prevent severe CO VID-19 from the delta variant requiring treatment by hospital.
In this article, we discuss how well VOCID-19 vaccines work against delta variants. We present current research.
how long will it take to build immunity after getting the covid-19 vaccine?
The report provides 71% after one dose and 92% after two doses of Oxford-AstraZeneca vaccine for protection from requiring COVID-19 hospital treatment. The Pfizer vaccine was 94% effective after the first and 96% after two doses to prevent hospitalization.
Covishield in India is the vaccine of Oxford-AstraZeneca COVID-19.
These percentages, which were not peer-reviewed, are equivalent to the alpha variant or B.1.1.7 which was first identified in the UK by scientists.
This follows a previous report indicating that vaccines COVID-19 were less effective in protecting people against COVID-19 when only the first dose of vaccines Pfizer-BioNTech or Oxford-AstraZeneca had been taken.
According to recent case study, yet to be evaluated, Moderna scientists found that antibodies from the volunteer vaccine trial could effectively neutralise a model virus carrying the delta variant mutations of the spike protein SARS-CoV-2.
The team examined the potential for neutralisation by the model virus or pseudovirus in serum, from eight volunteers receiving Moderna COVID 19 vaccine.
The researchers produced a number of these pseudoviruses, including the alpha variant first identified in the United Kingdom and the beta variant first identified in South Africa, which represented the Delta variant and other variants of concern.
Covaxin data & stats
A small study of scientists from the Indian Council of Medical Research, not yet peer-reviewed, and Bharat Biotech International, co-developing the Covaxin COVID-19 vaccine, reports on its efficacy against the delta.
The scientists concluded that vaccinated antibodies in the laboratory study were not so effective at neutralizing the virus variant. Nevertheless, they say that the “neutralization capacity” of the vaccine is well established. They give this the functioning of the vaccine.
The whole SARS-CoV-2 virus, which is chemically altered to prevent replication, consists of Covaxin.
If you receive the vaccine, your body can create antibodies from many different parts of the virus. If a part mutates to produce a new variant, like a delta variant, antibodies to other parts of the virus still need to provide adequate protection.
However, the study was small, and further research is needed to examine the efficacy of the Covaxin vaccine COVID-19 in real life to prevent serious COVID-19 from the delta variant.
Sputnik V and CoronaVac
On Twitter, the vaccine manufacturers of the Russian Spoutnik V vaccine COVID-19 recently announced that their delta vaccine is more effective than others. They added that they submitted the information to an international journal with peer review.
The company said it would soon offer a booster shot designed specifically to fight the delta variant.
It is not possible to evaluate the validity of these statements on the Sputnik V vaccine until the information is available to the public.
There is little data on the effectiveness of the Sinovac COVID-19 (CoronaVac) vaccine against the delta version. A news article in Reuters reported that, despite being received by CoronaVac, more than 350 doctors and medical workers in Indonesia have developed COVID-19.
The area has high infection rates, mainly due to the delta variant, according to experts. Given the Reuters report, more research is necessary to see exactly how well the delta variant can protect CoronaVac from severe COVID-19.